Monday, November 16, 2020

Carlyle's COVID Profit Plans

The Carlyle Group intends to profit from the global pandemic.  Carlyle's website states:

While the healthcare industry has permanently changed by the COVID-19 pandemic, it has also accelerated key themes that our Global Healthcare team has been consistently focused on for years.

Three healthcare industry themes that we believe have been accelerated by the coronavirus pandemic: 

  1. Increased emphasis on diversified healthcare delivery  (Brazilian hospital operator Rede D'or Sao Luis)
  2. A shift toward digital innovation and digital disruption (Grand Rounds, OneMedical)
  3. The importance of the bio-pharmaceutical revolution  (TriNetX, PPD, Albany Molecular Research, Piramal)

Carlyle failed to mention the other ways it plans to profit from COVID-19.

Carlyle affiliates can conduct retrospective studies on COVID-19 (TriNetX), disinfect surfaces (Victory Innovations), screen airports for people with fever (Schneider Electric & HGH), test for COVID antibodies (Ortho Clinical), assist with blood plasma collection (MAK Systems), produce antibody drug conjugate (Piramal Pharma Solutions), ensure the maximum hospital bill for COVID-19 patients (TrustHCS), manufacture Ivermectin treatment (SeQuent Scientific) and make federal coronavirus purchasing something other than a clown show (Unison). 

Coronavirus tea leaves suggest more PEU profits to come.  Those leave can be wrong.  Recall Carlyle drove LifeCare Hospitals and nursing home giant ManorCare into bankruptcy. 

More investment by the greed and leverage boys is not a good sign for people struggling to pay for healthcare in the United States.  

Update 3-13-21:  The former PECKER Council highlighted PEU entries in COVID-19 care.  PECKER is an abbreviation for Private Equity Capital Knowledge Executed Responsibly.

Update 6-9-24:  Carlyle exited Brazilian hospital operator Rede D'Or.